Tendie Bot

Tendie.bot

Login
CAPR Articles
reddit/

CAPR Surges 60%+ After-Hours on FDA BLA Update and Earnings: Retail Traders Eye Short Squeeze

Capricor Therapeutics (CAPR) saw a dramatic after-hours rally on August 14, 2026, after the company reported Q2 earnings and announced that the FDA is open to reviewing an amended Biologics License Application (BLA) for Deramiocel focusing on upper limb function. The stock jumped from $4.23 to as high as $7.70, triggering intense discussion on Reddit's r/Shortsqueeze, where traders highlighted a potential short squeeze with over 15 million shares short. The ticker's ranking on Tendie.bot soared 1,297 spots, reflecting the surge in retail attention.

  1. CAPR surged over 60% after-hours after Q2 earnings and an FDA update confirming it will review an amended BLA for Deramiocel.

  2. Retail traders on r/Shortsqueeze highlighted trapped short sellers, strong cash reserves of $237.9M, and a potential short squeeze setup.

  3. CAPR's ranking on Tendie.bot jumped 1,297 spots, signaling a massive spike in retail investor interest.

Capricor Therapeutics

CAPR
$CAPR became the center of retail investor attention on August 14, 2026, after the stock rocketed more than 60% in after-hours trading. The catalyst came from the company's Q2 earnings call, where management confirmed that the FDA is open to reviewing an amended Biologics License Application (BLA) for Deramiocel, focusing on upper limb function (PUL 2.0 endpoint, p=0.029). The stock, which closed regular trading at $4.23, surged to between $6.75 and $7.70, catching the eye of short-squeeze traders.

On r/Shortsqueeze, a detailed post argued that the setup was ripe for a massive short squeeze. The post noted that over 15.5 million shares were short, representing a significant portion of the float, and that the company's $237.9 million cash reserve eliminated the bear thesis of imminent dilution. The author pointed to institutional shorts being trapped and predicted that long funds would pile in, potentially triggering a full-blown squeeze. The post garnered 30 upvotes and 62 comments, reflecting strong engagement.

Another r/Shortsqueeze post featuring a short squeeze scan ranked CAPR among several candidates with high squeeze potential, while a post on r/smallstreetbets compared CAPR's setup to Ondas (ONDS), suggesting that CAPR's rise could be a precursor for other squeeze candidates. The overall sentiment on Reddit was cautiously bullish, with traders focused on the FDA update and the short interest dynamics.

CAPR

The FDA's willingness to review an amended BLA is a significant regulatory milestone for Capricor. The company's focus on upper limb function in Duchenne muscular dystrophy addresses a critical unmet need, and the positive trial results (p=0.029) provide a strong statistical basis. Combined with a robust cash position, the bear case that shorts had been betting on appears to have crumbled, at least in the eyes of retail traders.

Subscribe to Tendie.bot for more market recaps.